For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales - devices and disposables | 0 | 559* | 60 | 117 |
| Cost of goods sold | 0 | 102* | 25 | 38 |
| Gross profit | 0 | 457 | 35 | 79 |
| Research and development | 45 | 126 | 136 | 133 |
| Sales and marketing | 23 | 23 | 22 | 51 |
| General and administrative | 451 | 1,018 | 362 | 658 |
| Gain on remeasurement of deferred compensation conversion liability | 217 | - | - | - |
| Total operating expenses | 302 | 1,167 | 520 | 842 |
| Interest income | - | - | - | 0 |
| Loss from operations | -302 | -710 | -485 | -763 |
| Interest expense | 151 | 184 | 129 | 157 |
| Interest income | - | 0* | 0 | - |
| Inducement charge for warrants issued | 78 | - | - | - |
| Change in fair value of derivative liability | 13 | 76* | -37 | 30 |
| Gain from forgiveness of debt | 3 | 51* | 15 | - |
| Loss on extinguishment of debt | 0 | -836* | -106 | 0 |
| Gain from forgiveness of debt | - | - | - | 15 |
| Other income | 15 | 165* | 0 | - |
| Total other income (expense) | - | - | - | -48 |
| Total other income (expense) | -198 | -729 | -257 | 64 |
| Loss before income taxes | -500 | -1,216 | -742 | -811 |
| Provision for income taxes | 0 | 0 | 0 | 0 |
| Net loss | -500 | -1,216 | -742 | -811 |
| Deemed dividend | 510 | - | - | - |
| Preferred stock dividends | 3 | 26 | 43 | 45 |
| Net loss attributable to common stockholders | -1,013 | -1,242 | -785 | -856 |
| Basic EPS | -0.01 | -0.017 | -0.01 | -0.01 |
| Diluted EPS | -0.01 | -0.015 | -0.01 | -0.01 |
| Basic Average Shares | 88,836,000 | 75,139,000 | 81,689,000 | - |
| Diluted Average Shares | 88,836,000 | 84,838,000 | 81,689,000 | 78,838,000 |
GUIDED THERAPEUTICS INC (GTHP)
GUIDED THERAPEUTICS INC (GTHP)